The Hodgkin lymphoma drug known as cyclophosphamide (Cytoxan) may be significantly less effective for children, says a new study from researchers at the St. Jude Children's Research Hospital in Memphis, Tennessee. For the study they examined instances in which Cytoxan was adopted for treatment after the industry standard mechlorethamine (Mustargen) became unavailable.
They found that children who began taking the drug as a second option saw a 75 percent rate of event-free survival over two years. This is compared to an 88 percent rate with Mustargen.
"Our results suggest that even promising substitute regimens should be examined carefully before adoption; what might appear to be a suitable alternative regimen may result in an inferior outcome -- an intolerable situation for young people with curable diseases," the researchers wrote of their findings.
Their data appears in the December 27 issue of the New England Journal of Medicine.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.